Related Experiment Video

Updated: Jun 1, 2026

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

Inhibition by calmodulin antagonist trifluoperazine of experimental carcinogenesis in rat colon induced by

M Tatsuta1, H Iishi, M Baba

  • 1CTR ADULT DIS,DEPT PATHOL,OSAKA 537,JAPAN.

Oncology Reports
|May 25, 2011
PubMed

Insights

Trifluoperazine, a calmodulin antagonist, significantly reduced colon tumor development in rats. It also decreased colon cell proliferation and ornithine decarboxylase (ODC) activity during carcinogen administration.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Azoxymethane (AOM) is a chemical carcinogen used to induce colon tumors in research models.
  • Ornithine decarboxylase (ODC) is a key enzyme in polyamine synthesis, often upregulated during carcinogenesis.
  • Calmodulin antagonists, like trifluoperazine, interfere with calcium signaling pathways.

Purpose of the Study:

  • To investigate the effect of trifluoperazine on azoxymethane-induced colon carcinogenesis in Wistar rats.
  • To assess the impact of trifluoperazine on colon mucosa labeling index and ODC activity.
  • To explore the potential mechanism of trifluoperazine's anti-cancer effects.

Main Methods:

  • Wistar rats were administered azoxymethane to induce colon tumors.
  • Trifluoperazine was administered for prolonged periods.
  • Colon tumor incidence, colon mucosa labeling index, and colon wall ODC activity were measured.

Main Results:

  • Prolonged trifluoperazine administration significantly reduced the number of colon tumors by week 35.
  • Trifluoperazine significantly decreased colon mucosa labeling index and AOM-induced ODC activity during carcinogen administration.
  • These effects on ODC activity and labeling index were not observed after carcinogen cessation.

Conclusions:

  • Trifluoperazine demonstrates potential as a chemopreventive agent against colon cancer.
  • Inhibition of AOM-induced ODC activity and subsequent suppression of cell proliferation may be a key mechanism.
  • Further research into calmodulin antagonists for colon cancer prevention is warranted.

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.